ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
DNA Methylation Markers for Breast Cancer Detection in the Developing World.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.The Journal of clinical investigation · 2020Trial
- Development of the cf-MMSP Assay for Enhanced Analytical Sensitivity of Methylated DNA in Breast Cancer Liquid Biopsy.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Specific Marker Gene Analysis for Primary Central Nervous System Lymphoma Based on Methylation Difference and Development of Detection Primers.Brain and behavior · 2025Article
- DNA methylation biomarkers for the diagnosis and treatment management of breast cancer: where are we now?Epigenomics · 2025Review
- Factors Determining Women's Attitudes and Knowledge Toward Breast Cancer Screening: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Identification and validation of DNA methylation-driven gene OSR1 as a novel tumor suppressor for the diagnosis and prognosis of breast cancer.Frontiers in genetics · 2025Article
- Article
- Exploring prognostic DNA methylation genes in bladder cancer: a comprehensive analysis.Discover oncology · 2024Article
- Discovery and technical validation of high-performance methylated DNA markers for the detection of cervical lesions at risk of malignant progression in low- and middle-income countries.Clinical epigenetics · 2024Article
- Potential Role ofClinical Medicine Insights. Oncology · 2024Article
- Development of an automated liquid biopsy assay for methylated markers in advanced breast cancer.Cancer research communications · 2022Article
- Evaluating DNA Methylation in Random Fine Needle Aspirates from the Breast to Inform Cancer Risk.The breast journal · 2022Article
- High performance methylated DNA markers for detection of colon adenocarcinoma.Clinical epigenetics · 2021Article
- Automated and rapid detection of cancer in suspicious axillary lymph nodes in patients with breast cancer.NPJ breast cancer · 2021Article
- Clinical impact of PTEN methylation status as a prognostic marker for breast cancer.Journal, genetic engineering & biotechnology · 2021Article
- Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors.Clinical epigenetics · 2021Article
- Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer.World journal of surgical oncology · 2021Article
- Article
- A Novel Promoter CpG-Based Signature for Long-Term Survival Prediction of Breast Cancer Patients.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 7 institutions in 5 countries.
Funding
Abstract
purposeAn unmet need in low-resource countries is an automated breast cancer detection assay to prioritize women who should undergo core breast biopsy and pathologic review. Therefore, we sought to identify and validate a panel of methylated DNA markers to discriminate between cancer and benign breast lesions using cells obtained by fine-needle aspiration (FNA).
resultsIn the discovery cohort, 10 of 25 markers were selected that were highly methylated in breast cancer compared with benign tissues by QM-MSP. In the independent test cohort, this panel yielded an AUC of 0.937 (95% CI = 0.900-0.970). In the FNA pilot, we achieved an AUC of 0.960 (95% CI = 0.883-1.0) using the automated cartridge system.
conclusionsWe developed and piloted a fast and accurate methylation marker-based automated cartridge system to detect breast cancer in FNA samples. This quick ancillary test has the potential to prioritize cancer over benign tissues for expedited pathologic evaluation in poorly resourced countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.